Key Questions RAS Can Help You Answer

  • What is the current solid tumor clinical development landscape?

  • What are the key market impacting events?

  • What´s the strategy of major Oncology players?

  • What´s the positioning and strategy for a molecule of interest?

  • What are the upcoming innovation waves? What are the opportunities created by them?

  • What´s the current state-of-the-art in cancer biomarkers?

  • How to keep pace with the regulatory policies & payer positions across geographies?

  • What drug candidates/ companies are suitable for partnering or in-licensing for oncology therapeutics?

Featured Insights

June 11, 2019 / infographics, Oncology

Is AML Treatment Landscape At A Tipping Point?

The recent flurry of drug approvals has markedly altered the treatment landscape in AML providing patients with new opportunities. The space is getting more exciting as improved genetic testing, combinations of targeted therapies, and the advancement of immunotherapies will finally provide physicians options to advance beyond Walkman-era treatments.
Read More
August 16, 2018 / infographics, Oncology

Evolution In EGFRM+ Lung Cancer

Interest in the EGFR Lung cancer space initially started with the isolation of Epidermal growth factor (EGF) gene by Stanley Cohen in 1962 as a protein extracted from the mouse submaxillary gland that accelerated incisor eruption. Therefore, it was originally termed ‘tooth-lid factor’, but was later renamed EGF because it stimulated the proliferation of epithelial cells. Since then substantial progress has been made against lung cancer over the last two decades. Research has also powered the emergence of new targeted treatments which are helping patients live a longer and higher quality life after a lung cancer diagnosis. This infographic allows the reader to dwell deeper and look closely into the history of discovery, evolution and advancements pertaining to EGFR lung cancer space.
Read More
June 4, 2018 / ASCO18, infographics, Oncology

Major Milestones in Cancer Research

Research and development within the cancer field is continuously evolving and progressing. This infographic highlights the biggest milestones within the field of cancer research spanning 170 years —from the advent of general anesthesia opening the door for cancer surgery in the mid-1800s to the first gene therapy for cancer approved by the Food and Drug Administration in 2017.
Read More
May 25, 2018 / Featured Insights, Oncology

Nanotechnology in Drug Discovery and Design

This presentation takes the reader on an exciting journey, about the Science beneath the development of Oncology Nano Drug delivery systems. How the tumor mico and macro environments throws conspicuous challenges to the nanotech field? Furthermore, the presentation also gives a sneak view of Nanotherapeutics clinical landscape across development strategies and tumors.
Read More
July 18, 2017 / Biosimilars, Featured Insights, Oncology

Oncology Biosimilar Competitive Dynamics

This paper attempts to present situation analysis of the current marketplace of Oncology biosimilars specially with respect to the industry’s micro-environment. The research and analysis herein, intends to identify positive forces and interactions that are shaping an attractive biosimilar industry in both US and EU markets.
Read More

Read Our Blogs

May 31, 2017

Merck @ASCO 2017

Merck will present data for KEYTRUDA® Across 16 Types of Cancer at the 2017 ASCO Annual Meeting Researchers will present data from more than 50 abstracts investigating the use of KEYTRUDA as monotherapy and in novel combinations across 16 cancers, including NSCLC, melanoma, urothelial carcinoma, microsatellite instability-high (MSI-H) cancers, gastric […]
May 31, 2017

Pfizer @ASCO 2017

Pfizer will present more than 50 abstracts, involving more than 15 clinical-stage assets across solid and hematologic tumors and 12 moA, at the ASCO in Chicago from June 2-6, 2017. New data will be featured in 9 oral presentations from company-sponsored clinical trials, including a late-breaker on the investigational compound […]
May 31, 2017

Celgene @ASCO 2017

Celgene will demonstrate its broad range of Oncology Clinical Development Program evaluating its investigational pipeline & marketed products at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US, 2-6 June 2017. Presentations will include multiple solid tumor and blood cancers while highlighting the value of innovative […]
May 30, 2017

BMS @ASCO 2017

Bristol-Myers Squibb Research Showcases Expansive Oncology Clinical Development Program and Commitment to Exploring Novel Combinations at ASCO 2017 More than 80 presentations (including16 oral presentations and 7 poster discussions), highlighting data from Company-sponsored studies, collaborations and IS research spanning 20 types of cancer, with focus on research of precision therapies […]
May 30, 2017

AstraZeneca @ASCO 2017

AstraZeneca (AZ), along with its global biologics research and development arm, MedImmune, will demonstrate how it is rapidly delivering on the Company’s science-led strategy for transformational cancer medicine development at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US, 2-6 June 2017. With three new oncology […]
May 30, 2017

Amgen @ASCO 2017

Amgen announced that new clinical data and analyses from across its oncology portfolio will be presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 2-6, 2017. Oral Presentation of New Analysis on Limited Renal Toxicity Associated With XGEVA® (denosumab) Compared With Zoledronic […]

What would you like to know?